

## ASX ANNOUNCEMENT

### NAB Facilities – Expiry Extension

---

**1 October 2025** – Cann Group Limited (“Cann” or the “Company”) advises that it has received notice of a short-term extension from National Australia Bank (NAB) advising that the expiry dates of all NAB debt facilities (construction loan and working capital facility) have been extended from 30 September 2025 until 15 October 2025. All other terms and conditions of the facilities remain unchanged.

The Company and its lenders continue to collaborate on restructuring Cann’s debt arrangements, with this extension expected to allow sufficient time for Cann to substantially progress its refinancing initiatives which were outlined in its recent 2025 Annual Report.

**Authorised for release by the Board of Directors, Cann Group Limited.**

**For all other information please contact:**

Jenni Pilcher  
CEO & Managing Director  
Cann Group Limited  
+61 3 9095 7088  
[contact@cann grouplimited.com](mailto:contact@cann grouplimited.com)

Steven Notaro  
Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[contact@cann grouplimited.com](mailto:contact@cann grouplimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

**Learn more at:** [www.cann grouplimited.com](http://www.cann grouplimited.com) | [www.satipharm.com](http://www.satipharm.com)

For personal use only